Last reviewed · How we verify
Lumateperone LAI — Competitive Intelligence Brief
phase 1
Small molecule
Live · refreshed every 30 min
Target snapshot
Lumateperone LAI (Lumateperone LAI) — Intra-Cellular Therapies, Inc..
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Lumateperone LAI TARGET | Lumateperone LAI | Intra-Cellular Therapies, Inc. | phase 1 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Lumateperone LAI CI watch — RSS
- Lumateperone LAI CI watch — Atom
- Lumateperone LAI CI watch — JSON
- Lumateperone LAI alone — RSS
Cite this brief
Drug Landscape (2026). Lumateperone LAI — Competitive Intelligence Brief. https://druglandscape.com/ci/lumateperone-lai. Accessed 2026-06-10.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing